PIK3CA and meningioma: Importantly, our work identifies the therapeutic potential to target this axis using PI3K isoform inhibitors and endocrine manipulation, bridging molecular profiling, immune reprogramming, and metabolic regulation into a precision framework for a biologically distinct meningioma subtype [67].